EcoDrugPlus

Adam Metallopeptidase Domain 17

Ensembl ID : ENSCAFG00020026796
Gene Symbol: ADAM17
2 Cross references
282 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSCAFG00020026303
Gene Symbol: ADAMTS5
3 Cross references
199 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSCAFG00020000118
Gene Symbol: ADRM1
3 Cross references
261 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSCAFG00020008240
Gene Symbol: AKT1
3 Cross references
220 Possible Orthologues:

Akt Serine/threonine Kinase 2

Ensembl ID : ENSCAFG00020015563
Gene Symbol: AKT2
3 Cross references
257 Possible Orthologues:

Akt Serine/threonine Kinase 3

Ensembl ID : ENSCAFG00020000778
Gene Symbol: AKT3
3 Cross references
201 Possible Orthologues:

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSCAFG00020023746
Gene Symbol: ALK
3 Cross references
195 Possible Orthologues:

Atp Binding Cassette Subfamily B Member 1

Ensembl ID : ENSCAFG00020020692
Gene Symbol: ABCB1
3 Cross references
161 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSCAFG00020023468
Gene Symbol: ABCC1
3 Cross references
203 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 8

Ensembl ID : ENSCAFG00020017543
Gene Symbol: ABCC8
3 Cross references
245 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 9

Ensembl ID : ENSCAFG00020008129
Gene Symbol: ABCC9
3 Cross references
232 Possible Orthologues:

Atpase H+/k+ Transporting Subunit Alpha

Ensembl ID : ENSCAFG00020018799
Gene Symbol: ATP4A
3 Cross references
183 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).